DCM
CMPX icon

Difesa Capital Management’s Compass Therapeutics CMPX Stock Holding History

Difesa Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,337
Closed -$33K – 254
2021
Q4 		$33K Buy
+10,337
New +$34.3K 0.02% 167

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Difesa Capital Management's CMPX Position: Q1 2022 in Review

Difesa Capital Management sold out of Compass Therapeutics (CMPX) in Q1 2022, closing a stake of 10,337 shares — an estimated $33K sold.

Difesa Capital Management first reported a position in CMPX in Q4 2021 and held it in 1 quarter. The position peaked at $33K in Q4 2021. 34 funds tracked by Wall St. Rank hold CMPX as of Q1 2022.

  • Difesa Capital Management reported no remaining Compass Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Difesa Capital Management sold 10,337 Compass Therapeutics shares in Q1 2022, an estimated $33K.
  • Difesa Capital Management first reported a position in Compass Therapeutics in Q4 2021 and held it in 1 quarter.
  • Difesa Capital Management's Compass Therapeutics position peaked at $33K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2022.

Based on Difesa Capital Management's 13F filing for Q1 2022, filed 16 May 2022.